{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-273406","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.139995+00:00","generated_at":"2026-05-29T05:40:15.955110+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Verrica appoints David Zawitz as COO effective Dec 9; grants 950,000 option shares","bullets":["David Zawitz appointed Chief Operating Officer and principal operating officer, effective Dec 9, 2024.","Base salary of $250,000/year; target annual bonus of 40% of base salary.","Option grant for 950,000 shares at closing price on grant date, vesting over 4 years with accelerated vesting on change-in-control termination.","2024 Inducement Plan shares increased from 2,000,000 to 4,500,000 to accommodate the grant.","Zawitz to continue consulting for PBM Capital with Board approval for increased time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-273406","json":"https://secwatch.observer/filing/0001193125-24-273406.json","markdown":"https://secwatch.observer/filing/0001193125-24-273406.md","text":"https://secwatch.observer/filing/0001193125-24-273406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524273406/0001193125-24-273406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524273406/d878105d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:40:15.955110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}